Accelerometry and Its Association with Objective Markers of Walking Limitations in Ambulatory Adults with Multiple Sclerosis

Overview

Journal Arch Phys Med Rehabil

Specialty Rehabilitation Medicine

Date 2010 Nov 30

PMID 21112438

Citations 26

Authors

Robert W Motl

Deirdre Dlugonski

Yoojin Suh

Madeline Weikert

Bo Fernhall

Myla Goldman

Affiliations

Soon will be listed here.

Abstract

Objective: To validate accelerometry based on its correlations with 6-minute walk distance (6MWD) and oxygen cost of walking as objective markers of walking limitations in multiple sclerosis (MS).

Design: Cross-sectional.

Setting: Laboratory and general community.

Participants: Ambulatory participants with MS (N=26) who resided in the local community.

Interventions: Not applicable.

Main Outcome Measures: Patient Determined Disease Steps (PDDS) scale and Multiple Sclerosis Walking Scale-12 (MSWS-12); 6-minute walk test while wearing a portable metabolic unit for measuring the 6MWD and oxygen cost of walking; accelerometer during the waking hours of a 7-day period.

Results: The average of total daily movement counts from the accelerometer correlated significantly and strongly with MSWS-12 scores (ρ=-.681, P=.001), PDDS scores (ρ=-.609, P=.001), 6MWD (ρ=.519, P=.003), and oxygen cost of walking (ρ=-.541, P=.002).

Conclusions: We provide evidence that further supports the validity of accelerometry as a measure of walking limitations in ambulatory persons with MS.

Citing Articles

Within-person changes in objectively measured activity levels as a predictor of brain atrophy in multiple sclerosis.

Fitzgerald K, Sanjayan M, Dewey B, Niyogi P, Rjeily N, Fadlallah Y medRxiv. 2025; .

PMID: 39974055 PMC: 11838989. DOI: 10.1101/2025.01.27.25321205.

Psychometric assessment of the Persian version of the patient determined disease steps scale in patients with multiple sclerosis and neuromyelitis optica spectrum disorder.

Mirmosayyeb O, Shaygannejad V, Afsharzadeh M, Bataei R, Nehzat N, Mohammadi A Curr J Neurol. 2023; 21(4):206-210.

PMID: 38011336 PMC: 10189197. DOI: 10.18502/cjn.v21i4.11716.

Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.

Woelfle T, Bourguignon L, Lorscheider J, Kappos L, Naegelin Y, Jutzeler C J Med Internet Res. 2023; 25:e44428.

PMID: 37498655 PMC: 10415952. DOI: 10.2196/44428.

A Systematic Review of the Validity and Reliability of the Patient-Determined Disease Steps Scale.

Marrie R, McFadyen C, Yaeger L, Salter A Int J MS Care. 2023; 25(1):20-25.

PMID: 36711220 PMC: 9881423. DOI: 10.7224/1537-2073.2021-102.

Making Every Step Count: Minute-by-Minute Characterization of Step Counts Augments Remote Activity Monitoring in People With Multiple Sclerosis.

Block V, Waliman M, Xie Z, Akula A, Bove R, Pletcher M Front Neurol. 2022; 13:860008.

PMID: 35677343 PMC: 9167929. DOI: 10.3389/fneur.2022.860008.

References

Chetta A, Rampello A, Marangio E, Merlini S, Dazzi F, Aiello M . Cardiorespiratory response to walk in multiple sclerosis patients. Respir Med. 2004; 98(6):522-9. DOI: 10.1016/j.rmed.2003.11.011. View

Hobart J, Riazi A, Lamping D, Fitzpatrick R, Thompson A . Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology. 2003; 60(1):31-6. DOI: 10.1212/wnl.60.1.31. View

Snook E, Motl R, Gliottoni R . The effect of walking mobility on the measurement of physical activity using accelerometry in multiple sclerosis. Clin Rehabil. 2009; 23(3):248-58. DOI: 10.1177/0269215508101757. View

Motl R, Dlugonski D, Suh Y, Weikert M, Agiovlasitis S, Fernhall B . Multiple Sclerosis Walking Scale-12 and oxygen cost of walking. Gait Posture. 2010; 31(4):506-10. DOI: 10.1016/j.gaitpost.2010.02.011. View

Goldman M, Marrie R, Cohen J . Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2007; 14(3):383-90. DOI: 10.1177/1352458507082607. View

Motl R, Schwartz C, Vollmer T . Continued validation of the Symptom Inventory in multiple sclerosis. J Neurol Sci. 2009; 285(1-2):134-6. DOI: 10.1016/j.jns.2009.06.015. View

Butland R, Pang J, Gross E, Woodcock A, Geddes D . Two-, six-, and 12-minute walking tests in respiratory disease. Br Med J (Clin Res Ed). 1982; 284(6329):1607-8. PMC: 1498516. DOI: 10.1136/bmj.284.6329.1607. View

Motl R, Snook E . Confirmation and extension of the validity of the Multiple Sclerosis Walking Scale-12 (MSWS-12). J Neurol Sci. 2007; 268(1-2):69-73. DOI: 10.1016/j.jns.2007.11.003. View

Savci S, Inal-Ince D, Arikan H, Guclu-Gunduz A, Cetisli-Korkmaz N, Armutlu K . Six-minute walk distance as a measure of functional exercise capacity in multiple sclerosis. Disabil Rehabil. 2005; 27(22):1365-71. DOI: 10.1080/09638280500164479. View

10.

Hadjimichael O, Kerns R, Rizzo M, Cutter G, Vollmer T . Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2006; 127(1-2):35-41. DOI: 10.1016/j.pain.2006.07.015. View

11.

Weikert M, Motl R, Suh Y, McAuley E, Wynn D . Accelerometry in persons with multiple sclerosis: measurement of physical activity or walking mobility?. J Neurol Sci. 2010; 290(1-2):6-11. DOI: 10.1016/j.jns.2009.12.021. View

12.

Olgiati R, Jacquet J, di Prampero P . Energy cost of walking and exertional dyspnea in multiple sclerosis. Am Rev Respir Dis. 1986; 134(5):1005-10. DOI: 10.1164/arrd.1986.134.5.1005. View

13.

Waters R, Mulroy S . The energy expenditure of normal and pathologic gait. Gait Posture. 1999; 9(3):207-31. DOI: 10.1016/s0966-6362(99)00009-0. View

14.

McGuigan C, Hutchinson M . Confirming the validity and responsiveness of the Multiple Sclerosis Walking Scale-12 (MSWS-12). Neurology. 2004; 62(11):2103-5. DOI: 10.1212/01.wnl.0000127604.84575.0d. View

15.

Pearson O, Busse M, Van Deursen R, Wiles C . Quantification of walking mobility in neurological disorders. QJM. 2004; 97(8):463-75. DOI: 10.1093/qjmed/hch084. View

16.

Motl R, Snook E, Wynn D, Vollmer T . Physical activity correlates with neurological impairment and disability in multiple sclerosis. J Nerv Ment Dis. 2008; 196(6):492-5. DOI: 10.1097/NMD.0b013e318177351b. View